All the Active Ingredient Drugs
Topoisomerase I Inhibitor. Irinotecan HCl 20 mg/ml. CONC. FOR INFUS: 2 ml x 40 mg; 5 ml x
100 mg, 15 ml x 300 mg. Dosage should
be ajust. individ.
Tmt. of pts. with metastat. colorect.
cancer:
In comb. with 5-FU and folinic
acid in pts. without prior chemother. for
metastat. dis.
As a single agent in pts. who have failed
an established 5-FU contain.
tmt. regimen.
Tmt. of pts. with small cell lung canerc.
Tmt. of pts. with gastr. cancer.
Irinotecan in comb. with leucovorin and
5-FU for the first line
tmt. of pts. with metastatic pancreat.
adenocarcinoma.
C/I: Hypersens.
Chron. IBD and/or bowel obstruct.
Lact.
Bilirubin > 3 times the upper limit of the
normal range.
Severe bone marrow fail.
WHO performance status > 2.
Concom. use with St John’s Wort.
Live attenuat. vaccin.
Topoisomerase I Inhibitor. Irinotecan HCl 20 mg/ml. CONC. FOR INFUS: 2 ml x 40 mg; 5 ml x
100 mg, 25 ml x 500 mg. See lit.
Metastat. colorectal cancer either in comb.
with 5-fluorouracil and folinic acid in
patients without prior chemother. for
metastat. dis., or as single agent in pts.
who have failed an established
5-fluorouracil cont. tmt. regimen. Small
cell lung cancer, gastric cancer.
C/I: Chron. inflamm. bowel dis. and/or
bowel obstruct., hypersens., pregn., lact.,
bilirubin >3 times the upper limit of the
normal range, severe bone marrow
failure, WHO performance status > 2,
concom. use with St. John’s wort.
